Manzanita Pharmaceuticals

Timeline

1. Aug 20, 2025 Grant Government grant — SBIR: $1.09M (annual award, as published), announced Aug 20, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Funding

Last 2 years.

• Aug 20, 2025 Government grant — SBIR: $1.09M (annual award, as published), announced Aug 20, 2025. Agency: NIH/NCI. Source: government award database. source ↗

NIH awards 4

Annual award amounts. Total $3.2M.

• Sep 6, 2024 NIH award 1R44CA295214-01 FY2024: $905,526 awarded for that fiscal year; activity R44 (SBIR); PI KAHL, STEPHEN B; recipient as written: MANZANITA PHARMACEUTICALS, INC., WOODSIDE, CA. Toxicology (IND-enabling) studies source ↗
• Aug 23, 2018 NIH award 5R44CA180745-03 FY2018: $752,754 awarded for that fiscal year; activity R44 (SBIR); PI KAHL, STEPHEN B; recipient as written: MANZANITA PHARMACEUTICALS, INC., WOODSIDE, CA. Nonclinical development of Nervel source ↗
• Sep 25, 2017 NIH award 2R44CA180745-02 FY2017: $1,220,153 awarded for that fiscal year; activity R44 (SBIR); PI KAHL, STEPHEN B; recipient as written: MANZANITA PHARMACEUTICALS, INC., WOODSIDE, CA. Nonclinical development of Nerv source ↗
• Aug 19, 2013 NIH award 1R43CA180745-01 FY2013: $288,301 awarded for that fiscal year; activity R43 (SBIR); PI KAHL, STEPHEN B; recipient as written: MANZANITA PHARMACEUTICALS, INC., WOODSIDE, CA. In vivo feasibility of a peripher source ↗